Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 6:4:9.
doi: 10.1186/s40734-017-0055-1. eCollection 2017.

RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials

Khashayar Dashtipour  1 , Roongroj Bhidayasiri  2   3 , Jack J Chen  4   5 , Bahman Jabbari  6 , Mark Lew  7 , Diego Torres-Russotto  8
Affiliations
Review

RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials

Khashayar Dashtipour et al. J Clin Mov Disord. .

Abstract

Objective: The aim of this study was to examine the efficacy, safety and dosing practices of rimabotulinumtoxinB (BoNT-B) for the treatment of patients with sialorrhea based on a systematic review of clinical trials.

Methods: A systematic literature review was performed to identify randomized controlled trials and other comparative clinical studies of BoNT-B for the treatment of sialorrhea published in English between January 1999 and December 2015. Medical literature databases (PubMed, Cochrane Library, and EMBASE) were searched and a total of 41 records were identified. Of these, six primary publications that evaluated BoNT-B for the treatment of sialorrhea met criteria and were included in the final data report.

Synthesis: Total BoNT-B doses ranged from 1500 to 4000 units for sialorrhea. Most of the studies in sialorrhea showed statistically significant benefits of BoNT-B versus placebo (range 4-19.2 weeks). BoNT-B was generally well tolerated across the individual studies; most adverse events reported were considered unrelated to treatment. Adverse events considered potentially associated with BoNT-B included: dry mouth, change in saliva thickness, mild transient dysphagia, mild weakness of chewing and diarrhea.

Conclusions: BoNT-B significantly reduces sialorrhea at doses between 1500 and 4000 units. The relatively mild dose-dependent adverse events suggest both direct and remote toxin effects.

Keywords: Botulinum toxin type B; Drooling; Hypersalivation; Myobloc; Parkinson's disease; Sialorrhea.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram
See this image and copyright information in PMC

References

    1. Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:48–57. doi: 10.1016/j.tripleo.2005.08.018. - DOI - PubMed
    1. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV. Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121–123. doi: 10.1136/jnnp.69.1.121. - DOI - PMC - PubMed
    1. Ben-Aryeh H, Jungerman T, Szargel R, Klein E, Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry. 1996;39:946–949. doi: 10.1016/0006-3223(95)00296-0. - DOI - PubMed
    1. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother. 2000;34:662–665. doi: 10.1345/aph.19259. - DOI - PubMed
    1. Andersen PM, Gronberg H, Franzen L, Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci. 2001;191:111–114. doi: 10.1016/S0022-510X(01)00631-1. - DOI - PubMed

LinkOut - more resources